Navigation Links
Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy

ept) or placebo (Period B) and time to disease flare and safety were assessed, and an open-label phase designed to assess efficacy and long-term safety (Period C). Children in periods A and B remained on a stable dose of MTX and children in Period C were permitted one of three DMARDs in addition to ORENCIA. Data from Period C will be presented tomorrow. Results from Periods A and B were presented at the of Rheumatology Annual Scientific Meeting in November 2006.

Fifty-nine children randomized to placebo in Period B participated in Period C to receive open label treatment with ORENCIA. Thirty-three of them experienced a flare while 26 did not.

Everyone in Period C received 10 mg/kg of ORENCIA approximately every 28 days. Of the 33 children who received placebo and experienced disease flares during the Period B protocol-mandated withdrawal phase of up to six months, 80 percent had an ACR Pedi 30 response, 70 percent had an ACR Pedi 50 response, 50 percent had an ACR Pedi 70 Response and 27 percent had an ACR Pedi 90 response after re-introduction of therapy with ORENCIA in Period C.

Of the 26 children who received placebo during Period B who did not experience disease flares and then chose to receive open-label ORENCIA treatment during Period C, 76 percent had an ACR Pedi 30 response, 68 percent had an ACR Pedi 50 response, 60 percent had an ACR Pedi 70 Response and 36 percent had an ACR Pedi 90 response after re-introduction of therapy with ORENCIA in Period C.

Of the children who completed Period C, four (6.7 percent) children previously treated with placebo in Period B reported serious adverse events (SAEs) versus five (5.5 percent) children continuously treated with ORENCIA. All SAEs were considered unrelated to ORENCIA according to the investigator. None of these children discontinued due to an adverse event (AE). In addition, no child previously treated with placebo in Period B had an acute infusion reaction during the first infusion
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:6/18/2013)... 18, 2013  Specialty Coating Systems is ... Parylene coating technologies: SCS microRESIST™ Antimicrobial Parylene ... Parylene with antimicrobial properties to effectively eliminate ... (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ) ... and continue to pose a challenge to ...
(Date:6/18/2013)... , June 18, 2013  In a letter to ... , M.D., of Lake View, Iowa , ... receive annual influenza vaccine is neither scientifically justified nor ethically ... article in the summer issue of the Journal ... official statistics are correct, and an average of 36,000 patients ...
(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... includes coverage of the Middle East ... Market Access Tracker analyzes the challenges and opportunities ... in four international regions comprising 24 countries. The ...
Breaking Medicine Technology:Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3
... 18, 2011 Nile Therapeutics, Inc. (OTCQB: NLTX), ... heart failure patients, today announced that it has ... clinical trial evaluating pharmacokinetics (PK), pharmacodynamics (PD), safety ... of cenderitide in patients with chronic heart failure. ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... demonstrated in an IRB approved, randomized, placebo controlled, double-blinded ... has an impact on allergic rhinitis, a clinical condition ...
Cached Medicine Technology:Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 2Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 3Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 4Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™ 2Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™ 3
(Date:6/19/2013)... 19, 2013 Indosoft Inc., developers ... for Asterisk, announced today the availability of ... enhancement offers improved options for extracting, consolidating and ... effective contact center management. , Large Asterisk based ... as it happens from the call center software. ...
(Date:6/19/2013)... BEACH, Florida (PRWEB) June 19, 2013 ... an emphasis upon crystal meth addiction treatment, helping men ... this powerful drug. , Crystal meth is a stimulant ... manufactured. The drug is most commonly smoked, but it ... It is commonly created in homemade labs using common ...
(Date:6/19/2013)... June 19, 2013 CoachingWebsites, ... for coaches, announced today its affiliation with ... will offer exclusive websites and marketing solutions and ... “This new partnership with Active Intelligence shows our ... to its fullest,” says Greer Van Dyck, Online ...
(Date:6/19/2013)... The US Drug Watchdog says, ... specifically designed to help a recipient of a DePuy Pinnacle ... elevated levels of cobalt, and chromium, because we believe this ... device is doing. In the event the cobalt, or chromium ... the person will need to consider, including possible revision surgery ...
(Date:6/19/2013)... 19, 2013 The Mesothelioma Victims ... Control of the 2500 to 3000 citizens, who will ... mesothelioma this year, about one third will be US ... diagnosed with this asbestos exposure form of cancer, or ... access to the nations most skilled mesothelioma compensation settlement ...
Breaking Medicine News(10 mins):Health News:Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity 2Health News:Crystal Meth Addiction Treatment and Crystal Meth Drug Rehab Announced by Recovery Associates 2Health News:CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC 2Health News:US Drug Watchdog Now Urges Recipients Of A DePuy Pinnacle All Metal Hip Implant To Call Them About A Vital Blood Test To See If Their Hip Implant Device Has Failed 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3
... the leading cause of visual impairment and blindness in ... people. ,The American Academy of Ophthalmology ... there are new treatments that can usually recover lost ... ,The Academy encourages those older than 50 ...
... men who become impotent after prostate cancer surgery may find ... the penis,// which assists in restoring the lost erectile function, ... findings came to light after a study of nearly 44 ... erectile function, following its loss after treatment for prostate cancer. ...
... caused by meningococcal infection and the disease spreads like wild ... of weeks in the late 1990s. Mortality rate in cases ... Patients also run a high risk of serious disability after ... each year 170,000 people around the world die of this ...
... breakfast was recalled from Singapore's markets as a precautionary ... that the product might be contaminated and cause botulism, ... were told to recall Earth's Best Organic 2 Apple ... from the Agri-Food and Veterinary Authority. ,The ...
... to a recent study published in February 21 Journal ... cancer// are at a higher risk of developing a ... for childhood cancer have resulted in a current overall ... shown that these survivors are specifically at a higher ...
... distress should be evaluated for primary ciliary dyskinesia, a ... fibrosis. ,According to Thomas Ferkol, M.D., ... that about 80 percent of patients with primary ciliary ... ,"The diagnosis of PCD requires a high ...
Cached Medicine News:Health News:Spring is Time for Age-Related Macular Degeneration (AMD) Awareness 2Health News:Survivors of Childhood Cancers at Higher Risk for Secondary Cancer 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: